Biosplice Therapeutics Inc. has disclosed dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of cancer, diabetes and Alzheimer’s disease.
KRAS is a GTPase that switches from an active GTP-bound conformation and an inactive GDP-bound conformation. Recently, several covalent KRAS G12C inhibitors that stick the protein in its GDP-bound inactive state have reached the clinic. However, the clinical benefit to date is limited and there is a need for next-generation compounds with better target engagement.
Full-Life Technologies Ltd. has received IND clearance by the FDA, allowing it to conduct clinical trials of 225Ac-FL-020, its PSMA-targeted radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer.
Alternative splicing is known to play an important role in tissue development. Scientists at Brigham and Women’s Hospital have looked into the association between a chronic obstructive pulmonary disease (COPD) genetic variant and cell-specific splicing of putative ciliary rootlet coiled-coil protein-like 1 protein (CROCCP2).
Lung adenocarcinoma (LUAD) is a subtype of non-small-cell lung cancer (NSCLC) that represents around 40% of all lung tumors. Despite therapeutic advancements, LUAD remains a leading cause of cancer-related death worldwide. Previous research found that ferredoxin-1 (FDX1) dysregulation plays a role in LUAD progression. FDX1 is a crucial regulator of copper homeostasis and cuproptosis, a regulated form of cell death triggered by excessive copper levels.
Leyden Laboratories BV has patented polypeptides acting as spike glycoprotein (S) (SARS-CoV-2; COVID-19 virus) ligands reported to be useful for the treatment of SARS-CoV-2 infections.
Beta Pharma Inc. has presented 1,5-naphthyridine derivatives acting as GTPase KRAS (G12D mutant) and/or (G12C mutant) inhibitors and thus reported to be useful for the treatment of cancer.
Programmed cell death protein 1 (PD-1) is among the immune checkpoint molecules better explored in immunotherapy for cancer. However, it is necessary to obtain novel therapies where preclinical efficacy and safety data could translate into enhanced predictability of human efficacy, pharmacokinetics and side effects.
RSS
